title: CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.
abstract: Studies with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) monoinfection and HIV coinfection were highlighted at the 2013 Conference on Retroviruses and Opportunistic Infections (CROI). In HCV monoinfected patients, several interferon alfa-sparing, all-oral regimens demonstrated cure rates of greater than 90% with 12 weeks of treatment, including for hard-to-treat patients. Cure rates of 75% were attained in HIV/HCV coinfected patients with the addition of the investigational HCV protease inhibitor (PI) simeprevir to peginterferon alfa and ribavirin. Drug-drug interaction data to inform safe coadminstration of antiretroviral therapy with DAA-based HCV treatment were presented. There was continued emphasis on pathogenesis, management, and prevention of the long-term complications of HIV disease and its therapies, including cardiovascular disease, renal disease, alterations in bone metabolism, and vitamin D deficiency, along with a growing focus on biomarkers to predict development of end-organ disease. Understanding the elevated risk for non-AIDS-defining malignancies in the HIV-infected population and optimal management was a focal point of this year's data. Finally, the conference provided important information on tuberculosis coinfection and cryptococcal meningitis.
authors.affiliation: University of California San Francisco, San Francisco, CA, USA.
authors.forename: Anne F
authors.initials: AF
authors.lastname: Luetkemeyer
authors.forename: Diane V
authors.initials: DV
authors.lastname: Havlir
authors.forename: Judith S
authors.initials: JS
authors.lastname: Currier
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology; D016896:Treatment Outcome; D014808:Vitamin D Deficiency / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents